We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

UK biotech Bicycle Therapeutics has raised £40 million ($52m) in a new funding round to help it progress its pipeline, including its lead compound, a first-in-class cancer treatment. The company ...

Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports.

Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 3,940,000 ...

Cancer Research UK and its commercialisation arm are to work with UK biotech firm Bicycle Therapeutics on a novel approach to targeting cancer. Bicycle Therapeutics has developed a new class of ...

Bicycle Therapeutics' BT8009 offers strong safety and efficacy. Find out why BCYC stock could be a buy, despite recent volatility and awaiting mid-2025 data.

As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...

Bicycle Therapeutics plc (NASDAQ:BCYC) reported Q2 EPS of ($0.90), $0.06 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $4.38 million versus the ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology ...